Findings

What do systematic reviews say?

9 questions · 11 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 45.5%GRADE not reported 1 · 9.1%Very low 1 · 9.1%Low 1 · 9.1%Moderate 1 · 9.1%High 2 · 18.2%

LMWH prophylaxis vs fondaparinux prophylaxis

Total VTE · People with cancer with perioperative thromboprophylaxis

LMWH prophylaxis showed no clear difference in any VTE compared with fondaparinux prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for perioperative thromboprophylaxis in people with cancer 2018 · Cochrane Headline outcomes only
RR 2.51 [0.89, 7.03]
3 studies · 1806 participants
Low

Low molecular weight heparin vs no thromboprophylaxis

Total VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.57 [0.46, 0.71]
10 studies · 5743 participants
High

Unfractionated heparin vs no thromboprophylaxis

Total VTE · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin K antagonists vs placebo or no thromboprophylaxis

Total VTE · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antithrombin vs no thromboprophylaxis

Total VTE · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy

It is very uncertain whether antithrombin changes any VTE compared with no thromboprophylaxis (very low certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.84 [0.41, 1.73]
1 study · 85 participants
Very low

Low molecular weight heparin vs active control

Total VTE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in any VTE compared with with active control (1); GRADE not reported.

3 findings from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 4.81 [0.24, 95.58]
Studies not reported
GRADE not reported
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ultra‐low‐molecular‐weight heparin vs placebo

Total VTE · ambulatory cancer patients receiving chemotherapy

Ultra‐low‐molecular‐weight heparin leads to lower any VTE compared with placebo (high certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.36 [0.22, 0.6]
1 study · 3212 participants
High

DOAC vs placebo

Total VTE · ambulatory cancer patients receiving chemotherapy

DOAC probably leads to lower any VTE compared with placebo (moderate certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
RR 0.55 [0.34, 0.9]
2 studies · 1404 participants
Moderate

Vitamin K antagonists vs active control

Total VTE · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found